HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Objective To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization secondary to age-related macular degeneration....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2012-06, Vol.119 (6), p.1175-1183
Hauptverfasser:	Singer, Michael A., MD, Awh, Carl C., MD, Sadda, SriniVas, MD, Freeman, William R., MD, Antoszyk, Andrew N., MD, Wong, Pamela, MPH, Tuomi, Lisa, PharmD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biological and medical sciences Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Choroidal Neovascularization - physiopathology Female Follow-Up Studies Humans Intravitreal Injections Macular Degeneration - complications Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Medical sciences Miscellaneous Ophthalmology Ranibizumab Retinopathies Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!